Trials / Terminated
TerminatedNCT00883116
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 551 (actual)
- Sponsor
- R-Pharm · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed following first-line chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixabepilone | |
| DRUG | Doxorubicin | |
| DRUG | Paclitaxel |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2012-06-01
- Completion
- 2014-02-01
- First posted
- 2009-04-17
- Last updated
- 2017-03-09
- Results posted
- 2014-03-14
Locations
93 sites across 19 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Denmark, France, Greece, Hungary, Italy, Mexico, Norway, Peru, Russia, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00883116. Inclusion in this directory is not an endorsement.